Jul 31, 2019
ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective
Jul 30, 2019
ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics
Jun 26, 2019
ESSA Provides an Update to the Acquisition of Realm Therapeutics
Apr 10, 2019
Realm Therapeutics Announces 2018 Annual Report Available and Form 20-F Filing
Apr 05, 2019
Realm Therapeutics Announces Receipt of Nasdaq Listing Determination and Requests Hearing
Mar 29, 2019
Realm Therapeutics Announces Completion of Assets Disposal
Nov 29, 2018
Realm Therapeutics Provides Update on Strategic Review
Aug 08, 2018
Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
Aug 07, 2018
Realm Therapeutics to Report First Half 2018 Financial Results
Jul 10, 2018
Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis
Jul 04, 2018
Realm Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares
May 31, 2018
Realm Therapeutics to Present at June Investor Conferences
May 24, 2018
Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis
May 23, 2018
Realm Therapeutics Publicly Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares
May 21, 2018
Realm Therapeutics Presents Data Highlighting its Proprietary Immunomodulatory Technology's Potential in Acne and Psoriasis at IID 2018
May 02, 2018
Realm Therapeutics Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares
Apr 26, 2018
Realm Therapeutics plc ("Realm Therapeutics", "Realm", or the "Company") Notice of Full Year 2017 Results
Mar 12, 2018
Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic Conjunctivitis
Mar 08, 2018
Realm Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
Feb 27, 2018
Realm Therapeutics Strengthens its Patent Portfolio with Two New USPTO Notice of Allowances